Essential Thrombocythemia, Polycythemia Vera
Conditions
Brief summary
Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.
Detailed description
During one year, all patients with PV or ET followed in our centre, and who took a drug to treat their MPN, were identified. The investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug. After completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with PV or ET or SMF * Patients who took oral or sub-cutaneous drugs to treat their MPN. * Patients who agreed to complete the questionnaire
Exclusion criteria
* Patients with low risk PV or ET who do not take treatment * Patients unable to complete the questionnaire
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of adherence to drug prescription | At inclusion | prospective evaluation in a one shot questionnaire given to each treated patient seen at the consultation distributed between december 2014 and december 2015 |
Countries
France
Outcome results
None listed